Welcome to the Grant for Oncology Innovation

The Grant for Oncology Innovation (GOI) will not be accepting proposals for the award in its current format for 2018. EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany is committed to innovation and rewarding new thinking that could address the enormous unmet need in cancer care. To best address this, we are transforming the GOI to a more patient-centric focus. By connecting and empowering the oncology community, enabling and accelerating innovative drug discovery, and driving the clinical understanding of rare tumors with high unmet need, we will reach our shared goal – the delivery of innovative treatment to people with cancer. EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany will announce details of the new program in the coming months. Please check this website for updates.

The GOI is an initiative funded by EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany, which aims to support the advancement of science and medical research in the field of personalized treatment for solid tumors. The grant program was first launched to coincide with the European Cancer Congress (ECCO-ESMO-ESTRO) in Amsterdam, September 27 - October 1, 2013.

The three winners of the first GOI award were announced during an Awards Ceremony that took place in Madrid, Spain on Friday, September 26, 2014.

The two winners of the second GOI award were announced during an Awards Ceremony that took place in Vienna on Friday, September 25, 2015.

The winners of the third GOI award were announced during an Awards Ceremony that took place in Copenhagen on Sunday, October 9, 2016.

The three winners of the fourth GOI award were announced during an Awards Ceremony that took place in Madrid on Sunday, September 10, 2017.